RE:price target average about 7$ Are you irretrievably stupid?
Liminal management announced 4 days before Ryplazim approval that based on the 4050/ Fezagrapras Phase 1 MAD study results, Liminal would cancel the Phase 2 clinical trials for IPF and hyperglycademia, their only 2 Phase 2 trials for near term partnering.
Piper Sandler had a 37 page report based on market potential of IPF that followed Liminals excitement on IPF results with 4050. Most of their stock price target was based on IPF and when it failed, the price target was cut as there is nothing in pipeline that can be commercialized for several years. It really quite obvious why Piper Sandler updated their report based on news. It is difficult to understand why Liminal management releases this news right before PDUFA date and before they have analyzed all the other indications to possibly replace these failures. Makes you wonder what Thomson is doing? If 4050 does really suck, everyone was lying for years. If 4050 is great but they are burying it, that is criminal. One of these scenarios is very bad. Which one?
realstocky wrote: thats including piper b.s. price target of 4.50$ issued couple days before a FDA decision (who does that, and why?)...Mmmm